Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant Injection for Prevention of PONV
NCT06932107Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Feb 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Aprepitant Injection with Placebo (2 arms). Primary endpoint: Complete Response rates. Started Feb 2024; status: completed.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT06932107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932107.